[Form 4] Astrana Health Inc. Insider Trading Activity

Rhea-AI Filing Summary

Director John Chiang of Astrana Health, Inc. (ASTH) reported insider transactions on 08/13/2025. The filing shows an acquisition of 20,000 common shares through exercise of stock options at an effective price of $18.20 per share, and a separate disposition of 12,284 common shares sold at $29.63 per share. Following the reported transactions, the filing lists beneficial ownership amounts of 43,132 and 30,848 shares (the latter includes 6,449 restricted shares that vest by June 11, 2026 or at the issuer's 2026 annual meeting).

The form notes the exercised options were fully vested and exercisable. The report is signed by an attorney-in-fact on the reporting person's behalf.

Positive

• Acquisition of 20,000 shares via exercise of fully vested options at $18.20, increasing the director's direct stake
• Transparency on restricted shares: filing discloses 6,449 restricted shares and their vesting condition, clarifying future ownership

Negative

• Disposition of 12,284 shares at $29.63 reduces the director's immediately available holdings
• Restricted shares remain unvested (6,449 shares), limiting near-term voting power and liquidity for that portion

Insights

Securities Analyst

TL;DR: Director exercised vested options for 20,000 shares and sold 12,284 shares, modestly increasing directly held equity while realizing proceeds.

The director's exercise of options at $18.20 resulted in 20,000 newly acquired common shares, a straightforward cashless or paid exercise consistent with monetizing vested compensation. The contemporaneous sale of 12,284 shares at $29.63 suggests partial liquidation of holdings post-exercise or routine portfolio rebalancing. The filing discloses 6,449 restricted shares that remain subject to future vesting conditions, which limits immediate liquidity for that portion. Overall, the transactions are material to insider ownership tracking but do not alone indicate a change in control or significant dilution.

Corporate Governance Expert

TL;DR: Transactions reflect routine director compensation exercise and a taxable disposition; no governance red flags disclosed.

The report confirms the options were fully vested and exercisable at the time of exercise, meeting typical grant vesting conditions. The presence of restricted stock that vests by a specified corporate event is standard and aligns the director's incentives with shareholder meetings. There are no disclosures here of pledging, transfers to affiliates, or unusual derivative structures. From a governance perspective, these are normal insider activities but should be monitored alongside future filings for any pattern of consistent large-scale sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chiang John

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CA 91801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		M		20,000	A	$18.2	43,132	D
Common Stock	08/13/2025		F		12,284	D	$29.63	30,848(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$18.2	08/13/2025		M			20,000	(1)	11/11/2025	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. These stock options were fully vested and exercisable.

2. Includes 6,449 shares of restricted stock, which will vest on the earlier of June 11, 2026 or the date of the Issuer's 2026 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ASTH director John Chiang report?

He acquired 20,000 shares through exercise of stock options at $18.20 per share and disposed of 12,284 shares at $29.63 per share on 08/13/2025.

How many shares does John Chiang beneficially own after these transactions?

The filing lists beneficial ownership amounts of 43,132 and 30,848; the latter figure includes 6,449 restricted shares that are not yet vested.

Were the exercised options vested at the time of exercise?

Yes. The filing explicitly states the stock options were fully vested and exercisable.

When do the restricted shares vest?

The 6,449 restricted shares vest on the earlier of June 11, 2026 or the issuer's 2026 annual meeting of stockholders.

Do these transactions indicate a change in control of ASTH?

No such indication is made in the filing; the transactions appear to be personal exercises and a sale by the director rather than any control transfer.